LEADERS-FREE, a randomised double-blinded trial published in the New England Journal of Medicine (NEJM LEADERS FREE). The trial was designed to assess the combination of a short course (1 month) of DAPT with either the BioFreedom drug coated stent or the Gazelle BMS in patients with a high risk of bleeding.
- Oral anticoagulant treatment
- Elderly ≥ 75
- Low platelet count
- Previous bleeding
- Co-morbid disease (eg chronic renal failure or cancer)
Here Keith Oldroyd presents the results of LEADERS-FREE and how this may change the way we treat high risk population who often have the most to gain from revascularisation.